FrancophonIA/ELRC3.0 huggingface dataset:
English: Enurev Breezhaler administered at 44 micrograms once daily statistically significantly reduced breathlessness as evaluated by the Transitional Dyspnoea Index (TDI).
Estonian: Enurev Breezhaler 44 mikrogrammi üks kord ööpäevas vähendas statistiliselt oluliselt TDI (Transitional Dyspnoea Index) põhjal hinnatud hingeldust.
English: In a 3-week study where exercise tolerance was tested via cycle ergometer at submaximal (80%) workload (submaximal exercise tolerance test), Enurev Breezhaler, dosed in the morning, reduced dynamic hyperinflation and improved the length of time exercise could be maintained from the first dose onwards.
Estonian: 3-nädalases uuringus, kus koormustaluvust hinnati veloergomeetri abil submaksimaalsel (80%) koormusel (submaksimaalne koormustaluvuse test), vähenes hommikul manustatud Enurev Breezhaleri toimel dünaamiline hüperinflatsioon ja paranes koormustaluvuse aeg alates esimesest annusest.
English: • Do not use the Enurev Breezhaler capsules with any other inhaler.
Estonian: • Ärge kasutage Enurev Breezhaleri kapsleid üheski teises inhalaatoris.
English: Talk to your doctor before using Enurev Breezhaler, if any of the following applies to you: - you have kidney problems.
Estonian: Enne Enurev Breezhaleri kasutamist pidage nõu oma arstiga, kui midagi järgnevalt loetletust kehtib teie kohta: - kui teil on probleeme neerudega.
English: Enurev Breezhaler contains lactose
Estonian: Enurev Breezhaler sisaldab laktoosi
English: In patients with severe renal impairment or end-stage renal disease requiring dialysis Enurev Breezhaler should be used only if the expected benefit outweighs the potential risk since the systemic exposure to glycopyrronium may be increased in this population (see sections 4.4 and 5.2).
Estonian: Raske neerukahjustuse või dialüüsi vajava lõppstaadiumis neeruhaigusega patsientidel tohib Enurev Breezhalerit kasutada ainult juhul, kui ravist oodatav kasu ületab võimaliku riski, sest antud populatsioonis võib glükopürrooniumi plasmakontsentratsioon olla suurenenud (vt lõigud 4.4 ja 5.2).
English: The magnitude of the effect was dependent on the degree of reversibility of airflow limitation at baseline (tested by administration of a short-acting muscarinic antagonist bronchodilator): Patients with the lowest degree of reversibility at baseline (<5%) generally exhibited a lower bronchodilator response than patients with a higher degree of reversibility at baseline (≥5%).
Estonian: Toime tugevus oli sõltuv hingamisteede obstruktsiooni pöörduvuse astmest uuringu alguses (kontrollitud manustades lühitoimelist muskariiniretseptoritesse toimivat bronhodilataatorit): Patsientidel, kellel oli algselt madalaim pöörduvuse aste (<5%) esines nõrgem vastus bronhodilataatorile kui patsientidel, kellel oli uuringu alguses kõrgem pöörduvuse aste
English: When to inhale Enurev Breezhaler Use this medicine at the same time each day.
Estonian: Millal Enurev Breezhalerit sisse hingata Kasutage seda ravimit iga päev samal kellaajal.
English: In the pooled 6-month database the frequency of dry mouth was 2.2% versus 1.1%, of insomnia 1.0% versus 0.8%, and of gastroenteritis 1.4% versus 0.9%, for Enurev Breezhaler and placebo respectively.
Estonian: Kombineeritud esimese 6 kuu andmete alusel oli suukuivuse esinemissagedus Enurev Breezhaleri ja platseebo kasutamisel vastavalt 2,2% versus 1,1%, unetuse esinemissagedus 1,0% versus 0,8% ning gastroenteriidi esinemissagedus 1,4% versus 0,9%.
English: Other medicines and Enurev Breezhaler
Estonian: Muud ravimid ja Enurev Breezhaler
English: Do not use Enurev Breezhaler - if you are allergic to glycopyrronium bromide or any of the other ingredients of this medicine
Estonian: Ärge kasutage Enurev Breezhalerit - kui olete glükopürrooniumbromiidi või selle ravimi mis tahes koostisosade (loetletud lõigus 6)
English: What Enurev Breezhaler contains - The active substance is glycopyrronium bromide.
Estonian: Mida Enurev Breezhaler sisaldab - Toimeaine on glükopürrooniumbromiid.
English: Enurev Breezhaler once daily statistically significantly reduced the use of rescue medication (salbutamol) by 0.46 puffs per day (p=0.005) over 26 weeks and by 0.37 puffs per day (p=0.039) over 52 weeks, compared to placebo for the 6- and 12-month studies, respectively.
Estonian: Enurev Breezhaleri manustamisel üks kord ööpäevas vähenes statistiliselt oluliselt hooravimi (salbutamooli) kasutamine 0,46 inhalatsiooni võrra päevas (p=0,005) 26 nädala jooksul ja 0,37 inhalatsiooni võrra päevas (p=0,039) 52 nädala jooksul võrreldes platseeboga vastavalt 6 ja 12 kuud kestnud uuringutes.
English: In the 6-month study, the percentage of patients experiencing a moderate or severe exacerbation was 17.5% for Enurev Breezhaler and 24.2% for placebo (Hazard ratio: 0.69, p=0.023), and in the 12-month study it was 32.8% for Enurev Breezhaler and 40.2% for placebo (Hazard ratio: 0.66, p=0.001).
Estonian: 6-kuulises uuringus oli mõõduka või raske ägenemisega patsientide osakaal Enurev Breezhaleriga 17,5% ja platseeboga 24,2% (riskisuhe: 0,69, p=0,023) ning 12-kuulises uuringus Enurev Breezhaleriga 32,8% ja platseeboga 40,2% (riskisuhe: 0,66, p=0,001).
English: The co-administration of Enurev Breezhaler with other anticholinergic-containing medicinal products has not been studied and is therefore not recommended.
Estonian: Enurev Breezhaleri manustamist koos teiste antikolinergilisi aineid sisaldavate ravimitega ei ole uuritud ning seetõttu ei ole koosmanustamine soovitatav.
English: In the 12-month study, Enurev Breezhaler produced statistically significant improvements in FEV1 compared to tiotropium in the first 4 hours after dosing on day 1 and at week 26, and numerically greater values for FEV1 in the first 4 hours after dosing than tiotropium at week 12 and week 52.
Estonian: 12-kuulises uuringus viis Enurev Breezhaleri kasutamine FEV1 statistiliselt olulise paranemiseni võrreldes tiotroopiumiga esimese 4 tunni jooksul pärast manustamist 1. päeval ja 26. nädalal ning FEV1 arvuliselt suuremate väärtusteni esimese 4 tunni jooksul pärast manustamist võrreldes tiotroopiumiga 12. nädalal ja 52. nädalal.
English: • Do not use the Enurev Breezhaler inhaler to take any other capsule medicine.
Estonian: • Ärge kasutage Enurev Breezhaleri inhalaatorit ühegi teise ravimi manustamiseks.
English: Your Seebri Breezhaler Inhaler pack contains:
Estonian: Teie Enurev Breezhaleri pakend sisaldab:
English: After three weeks of treatment the improvement in inspiratory capacity with Enurev Breezhaler was similar to the first day (200 ml), exercise endurance time however had increased by 89 seconds (an increase of 21%) compared to placebo.
Estonian: Pärast kolm nädalat kestnud ravi oli inspiratoorse kapatsiteedi suurenemine Enurev Breezhaleri kasutamisel sarnane esimese päevaga (200 ml), kuid koormustaluvuse aeg oli pikenenud 89 sekundi võrra (21% tõus) võrreldes platseeboga.
English: If you forget to use Enurev Breezhaler
Estonian: Kui te unustate Enurev Breezhalerit kasutada
English: At 12 weeks (primary endpoint), Enurev Breezhaler increased trough FEV1 by 108 ml in the 6-month study and by 97 ml in the 12-month study compared to placebo (both p<0.001).
Estonian: 12 nädala möödudes (esmane tulemusnäitaja) suurenes Enurev Breezhaleri toimel minimaalne FEV1 6-kuulises uuringus 108 ml ja 12-kuulises uuringus 97 ml võrreldes platseeboga (mõlemad p<0,001).
English: Peak plasma levels and total systemic exposure following intravenous administration of 150 micrograms glycopyrronium bromide (equivalent to 120 micrograms glycopyrronium) in healthy volunteers were respectively about 50-fold and 6-fold higher than the peak and total exposure at steady-state achieved with the recommended dose (44 micrograms once daily) of Enurev Breezhaler and were well tolerated.
Estonian: Tervetel vabatahtlikel olid 150 mikrogrammi glükopürrooniumbromiidi (vastab 120 mikrogrammile glükopürrooniumile) veenisisese manustamise järgne maksimaalne plasmakontsentratsioon (Cmax) ja kontsentratsiooni-kõvera alune pindala (AUC) vastavalt umbes 50 ja 6 korda suuremad kui Enurev Breezhaleri soovitatava annuse (44 mikrogrammi üks kord ööpäevas) manustamisel inhalatsiooni teel ning olid hästi talutavad.
English: Enurev Breezhaler should be used with caution in these patient groups.
Estonian: Nendes patsendirühmades tuleb Enurev Breezhalerit kasutada ettevaatusega.
English: At 12 weeks (primary endpoint), Enurev Breezhaler increased trough FEV1 by 72 ml in patients with the lowest degree of reversibility (<5%) and by 113 ml in those patients with a higher degree of reversibility at baseline (≥5%) compared to placebo (both p<0.05).
Estonian: Võrreldes platseeboga oli 12 nädala pärast (esmane tulemusnäitaja) Enurev Breezhaleriga minimaalne FEV1 suurenenud 72 ml võrra patsientidel, kellel oli algselt madalaim pöörduvuse aste (<5%) ja 113 ml võrra patsientidel, kellel oli algselt kõrgem pöörduvuse aste (≥5%) (mõlemal juhul p<0,05).
English: Show the pack of Enurev Breezhaler.
Estonian: Näidake neile Enurev Breezhaleri pakendit.
English: Enurev Breezhaler can be used at the recommended dose in elderly patients (75 years of age and older) (see section 4.8).
Estonian: Eakatel patsientidel (75-aastased ja vanemad) võib Enurev Breezhalerit kasutada soovitatud annuses (vt lõik 4.8).
English: Please read the full Instructions for Use before using the Enurev Breezhaler.
Estonian: Enne Enurev Breezhaleri kasutamist lugege palun täielikku kasutamisjuhendit.
English: In patients with severe renal impairment (eGFR <30 ml/min/1.73 m2), including those with end-stage renal disease requiring dialysis, Enurev Breezhaler should only be used if the expected benefit outweighs the potential risk (see section 4.4).
Estonian: Raske neerukahjustusega patsientidel (eGFR <30 ml/min/1,73 m2), kaasa arvatud dialüüsi vajava lõppstaadiumis neeruhaiguse korral tohib Enurev Breezhalerit kasutada ainult juhul, kui oodatav kasu ületab võimaliku riski (vt lõik 4.4).
English: Enurev Breezhaler is a once-daily, long-term maintenance treatment and is not indicated for the initial treatment of acute episodes of bronchospasm, i.e. as a rescue therapy.
Estonian: Ravim ei ole näidustatud ägedate haigushoogude raviks Enurev Breezhalerit kasutatakse üks kord ööpäevas manustatava pikaajalise säilitusravina ning see ei ole näidustatud ägedate bronhospasmi episoodide esmaseks raviks, st hooravimina.
English: In a pooled analysis of the first 6 months of treatment in the 6- and 12-month studies, compared to placebo Enurev Breezhaler statistically significantly prolonged time to first moderate or severe exacerbation and reduced the rate of moderate or severe COPD exacerbations (0.53 exacerbations/year versus 0.77exacerbations /year, p<0.001).
Estonian: 6- ja 12-kuulise keskse uuringu koondanalüüs esimese 6 ravikuu põhjal näitas, et võrreldes platseeboga pikendas Enurev Breezhaler statistiliselt oluliselt aega esimese mõõduka või raske ägenemiseni ning vähendas mõõdukate ja raskete ägenemiste esinemissagedust (0,53 ägenemist aastas versus 0,77 ägenemist aastas, p<0,001).
English: What Enurev Breezhaler is and what it is used for
Estonian: Mis ravim on Enurev Breezhaler ja milleks seda kasutatakse
English: In the 6-month study, Enurev Breezhaler increased FEV1 after the first dose with an improvement of 93 ml within 5 minutes and 144 ml within 15 minutes of dosing, compared to placebo (both p<0.001).
Estonian: 6 kuud kestnud uuringus suurenes Enurev Breezhaleri toimel FEV1 pärast esimest annust, paranedes 93 ml võrra 5 minutil ja 144 ml võrra 15 minutil pärast ravimi manustamist võrreldes platseeboga (mõlemad p<0,001).
English: Enurev Breezhaler 44 mcg inhalation powder glycopyrronium
Estonian: Enurev Breezhaler 44 µg inhalatsioonipulber glycopyrronium
English: What you need to know before you use Enurev Breezhaler
Estonian: Mida on vaja teada enne Enurev Breezhaleri kasutamist
English: Enurev Breezhaler is a single-dose inhaler.
Estonian: Enurev Breezhaler on inhalaator ühekordse annuse manustamiseks.
English: Only use the capsules with the inhaler provided in this pack (Enurev
Estonian: Kasutage kapsleid ainult koos selles pakendis oleva inhalaatoriga (Enurev Breezhaler inhalaator).
English: There are no data from the use of Enurev Breezhaler in pregnant women.
Estonian: Glükopürrooniumi kasutamise kohta rasedatel andmed puuduvad.
English: Enurev Breezhaler also reduced dyspnoea at rest measured using the Transitional Dyspnoea Index.
Estonian: Enurev Breezhaleri toimel vähenes hingeldus ka puhkeolekus, mida mõõdeti TDI (Transitional Dyspnoea Index) järgi.
English: In patients with severe renal impairment (estimated glomerular filtration rate below 30 ml/min/1.73 m2), including those with end-stage renal disease requiring dialysis, Enurev Breezhaler should be used only if the expected benefit outweighs the potential risk (see section 5.2).
Estonian: Raske neerukahjustusega patsientidel (hinnanguline glomerulaarfiltratsiooni kiirus alla 30 ml/min/1,73 m2), kaasa arvatud dialüüsi vajava lõppstaadiumis neeruhaiguse korral tohib Enurev Breezhalerit kasutada ainult juhul, kui oodatav kasu ületab võimalikud riskid (vt lõik 5.2).
English: Enurev Breezhaler is recommended to be administered, at the same time of the day each day.
Estonian: Enurev Breezhalerit on soovitatav kasutada iga päev samal kellaajal.
English: Patients with hepatic impairment Clinical studies have not been conducted in patients with hepatic impairment.
Estonian: Maksakahjustusega patsientidel ei ole kliinilisi uuringuid läbi viidud.
English: Patients with severe renal impairment
Estonian: Raske neerukahjustusega patsiendid
English: No specific side effects have been reported when Enurev Breezhaler has been used together with other medicines used to treat COPD such as reliever inhalers (e.g. salbutamol), methylxanthines (e.g. theophylline) and/or oral and inhaled steroids (e.g. prednisolone).
Estonian: Kasutades Enurev Breezhalerit koos teiste KOKi ravis kasutatavate ravimitega, nagu inhalaatorid sümptomite leevendamiseks (nt salbutamool), metüülksantiinid (nt teofülliin) ja/või suukaudsed ja inhaleeritavad kortikosteroidid (nt prednisoloon), ei ole teatatud spetsiifilistest kõrvaltoimetest.
English: Enurev Breezhaler was found to decrease dyspnoea and leg discomfort when exercising as measured using Borg scales.
Estonian: Leiti, et Enurev Breezhaleri toimel väheneb hingeldus ja ebamugavustunne jalgades koormuse ajal, mõõdetuna Borgi skaaladel.
English: • One Seebri Breezhaler inhaler
Estonian: • Ühte Enurev Breezhaleri inhalaatorit
English: A pooled analysis of the 6- and 12-month pivotal studies found a statistically significantly higher percentage of patients receiving Enurev Breezhaler responded with a 4 point or greater improvement in SGRQ compared to placebo at week 26 (57.8% and 47.6% respectively, p<0.001).
Estonian: 6 ja 12 kuud kestnud kesksete uuringute koondanalüüsi põhjal saavutas statistiliselt oluliselt suurem protsent Enurev Breezhalerit saanud patsientidest SGRQ paranemise nelja või enama punkti võrra 26. nädalal võrreldes platseeboga (vastavalt 57,8% ja 47,6%, p<0,001).
English: How much Enurev Breezhaler to use
Estonian: Kui palju Enurev Breezhalerit kasutada
English: Although no formal drug interaction studies have been performed, Enurev Breezhaler has been used concomitantly with other medicinal products commonly used in the treatment of COPD without clinical evidence of drug interactions.
Estonian: Kuigi spetsiaalseid ravimite koostoimeuuringuid ei ole Enurev Breezhaleriga läbi viidud, ei ole täheldatud koostoimeid Enurev Breezhaleri ja sagedasti kasutatavate KOKi ravimite kooskasutamisel.
English: Acute intoxication by inadvertent oral ingestion of Enurev Breezhaler capsules is unlikely due to the low oral bioavailability (about 5%).
Estonian: Väikese suukaudse biosaadavuse (umbes 5%) tõttu ei ole Enurev Breezhaler kapslite tahtmatu suukaudse sissevõtmise järgselt ägeda mürgistuse teke tõenäoline.
English: Immediate hypersensitivity reactions have been reported after administration of Enurev Breezhaler.
Estonian: On teatatud kiiret tüüpi ülitundlikkusreaktsioonidest pärast Enurev Breezhaleri manustamist.
English: In a pooled analysis of the 6and 12-month pivotal studies a statistically significantly higher percentage of patients receiving Enurev Breezhaler responded with a 1 point or greater improvement in the TDI focal score at week 26 compared to placebo (58.4% and 46.4% respectively, p<0.001).
Estonian: 6 ja 12 kuud kestnud kesksete uuringute koondanalüüsi põhjal saavutas statistiliselt oluliselt suurem protsent Enurev Breezhalerit saanud patsientidest TDI skoori paranemise ühe või enama punkti võrra 26. nädalal võrreldes platseeboga (vastavalt 58,4% ja 46,4%, p<0,001).
English: No change in mean heart rate or QTc interval was observed with Enurev Breezhaler in doses up to 176 micrograms in COPD patients.
Estonian: KOKi haigetel ei täheldatud Enurev Breezhaleri kasutamisel annustes kuni 176 mikrogrammi keskmise südame löögisageduse ega QTc-intervalli muutust.
English: Enurev Breezhaler 44 micrograms inhalation powder, hard capsules glycopyrronium (as glycopyrronium bromide)
Estonian: Enurev Breezhaler 44 mikrogrammi inhalatsioonipulber kõvakapslis glycopyrronium (glycopyrronii bromidum)
English: Instructions for use of Enurev Breezhaler inhaler
Estonian: Enurev Breezhaler inhalaatori kasutusjuhend
English: Enurev Breezhaler 44 micrograms inhalation powder, hard capsules
Estonian: Enurev Breezhaler 44 mikrogrammi inhalatsioonipulber kõvakapslis
English: The pooled analysis also showed fewer patients treated with Enurev Breezhaler than with placebo experienced an exacerbation requiring hospitalisation (1.7% versus 4.2%, p=0.003).
Estonian: Koondanalüüs esimese 26 ravinädala põhjal näitas ka, et haiglaravi vajanud ägenemine tekkis väiksemal arvul Enurev Breezhaleriga ravitud patsientidel võrreldes platseeboga (1,7% versus 4,2%, p=0,003).
English: How to use Enurev Breezhaler
Estonian: Kuidas Enurev Breezhalerit kasutada
English: How to store Enurev Breezhaler
Estonian: Kuidas Enurev Breezhalerit säilitada
English: What Enurev Breezhaler is used for
Estonian: Milleks Enurev Breezhalerit kasutatakse
English: There is no relevant use of Enurev Breezhaler in the paediatric population (under 18 years) in the indication COPD.
Estonian: Lapsed Puudub Enurev Breezhaleri asjakohane kasutus lastel vanuses kuni 18 aastat KOKi näidustusel.
English: 24 x 1 capsules + 1 inhaler.
Estonian: 24x1 kapslit + 1 inhalaator.
English: 6 x 1 capsules + 1 inhaler.
Estonian: 6x1 kapslit + 1 inhalaator.
English: The inhaler provided with each new prescription should be used.
Estonian: Kasutada tuleb Enurev Breezhaler inhalaatorit, mis on iga uue väljakirjutatud ravimi pakendis.
English: 30 x 1 capsules + 1 inhaler.
Estonian: 30x1 kapslit + 1 inhalaator.
English: Enurev Breezhaler is used as a maintenance treatment for your COPD.
Estonian: Enurev Breezhalerit kasutatakse KOKi säilitusraviks.
English: What Enurev Breezhaler is
Estonian: Mis ravim on Enurev Breezhaler
English: Zejula niraparib
Estonian: Zejula nirapariib
English: The dose is 3 capsules per day, taken together at the same time each day.
Estonian: Annus on 3 kapslit ööpäevas, mis võetakse korraga sisse iga päev samal ajal.
English: Treatment should continue until the disease gets worse.
Estonian: Ravi peab jätkuma kuni haiguse süvenemiseni.
English: What measures are being taken to ensure the safe and effective use of Zejula?
Estonian: Mis meetmed võetakse, et tagada Zejula ohutu ja efektiivne kasutamine?
English: The European Medicines Agency therefore decided that Zejula's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Seetõttu otsustas Euroopa Ravimiamet, et Zejula kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: The most common side effects with Zejula (which may affect more than 1 in 10 people) are nausea (feeling sick), thrombocytopenia (low blood platelet counts), tiredness and weakness, anaemia (low red blood cell counts), constipation, vomiting, abdominal (belly) pain, neutropenia (low levels of neutrophils, a type of white blood cell), insomnia (difficulty sleeping), headache, lack of appetite, nasopharyngitis (inflammation of the nose and throat), diarrhoea, dyspnoea (difficulty breathing), hypertension (high blood pressure), dyspepsia (heartburn), back pain, dizziness, cough, urinary tract infection (infection of the structures that carry urine), joint pain, palpitations and dysgeusia (taste disturbances).
Estonian: Zejula kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on iiveldus, trombotsütopeenia (vereliistakute väike sisaldus), väsimus ja nõrkus, aneemia (punaliblede väike sisaldus), kõhukinnisus, oksendamine, kõhuvalu, neutropeenia (teatud tüüpi valgeliblede, neutrofiilide väike sisaldus), unetus, peavalu, isupuudus, nasofarüngiit (ninaneelupõletik), kõhulahtisus, düspnoe (hingamisraskus), hüpertensioon (kõrge vererõhk), düspepsia (kõrvetised), seljavalu, peapööritus, köha, kuseteede nakkus, liigesevalu, südamepekslemine ja maitsemeele häired.
English: Other information about Zejula
Estonian: Muu teave Zejula kohta
English: Zejula is available as capsules (100 mg) to be taken by mouth.
Estonian: Zejulat turustatakse suukaudsete kapslitena (100 mg).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zejula have been included in the summary of product characteristics and the package leaflet.
Estonian: Zejula ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Although treatments for advanced, relapsed ovarian cancer are available, the disease inevitably comes back again.
Estonian: Kuigi kaugelearenenud retsidiveerunud munasarjavähi jaoks on ravimid olemas, tuleb haigus paratamatult lõpuks tagasi.
English: Treatment may be interrupted and the dose may be reduced in patients who experience side effects.
Estonian: Ravi võib katkestada ja annust vähendada patsientidel, kellel ilmnevad kõrvalnähud.
English: Why is Zejula approved?
Estonian: Miks Zejula heaks kiideti?
English: What is Zejula and what is it used for?
Estonian: Mis on Zejula ja milleks seda kasutatakse?
English: The medicine is given after treatment with platinumbased medicines, when the tumour is diminishing in size or has completely disappeared.
Estonian: Ravimit manustatakse pärast ravi plaatinapreparaatidega, kui kasvaja suurus on vähenenud või kasvaja on täielikult kadunud.
English: Serious side effects include thrombocytopenia and anaemia.
Estonian: Raskete kõrvalnähtude hulka kuuluvad trombotsütopeenia ja aneemia.
English: The active substance in Zejula, niraparib, blocks the action of enzymes called PARP-1 and PARP-2, which help to repair damaged DNA in cells when the cells divide to make new cells.
Estonian: Zejula toimeaine nirapariib blokeerib PARP-1 ja PARP-2 ensüümide toime, mis aitavad rakkudes parandada kahjustatud DNA-d, kui toimub rakkude jagunemine rakkude paljunemise eesmärgil.
English: Because the number of patients with ovarian cancer is low, the disease is considered ‘rare', and Zejula was designated an ‘orphan medicine' (a medicine used in rare diseases) on 4 August 2010.
Estonian: Et munasarjavähiga patsientide arv on väike ja see haigus esineb harva, nimetati Zejula 4. augustil 2010 harvikravimiks.
English: Regarding safety, side effects are generally manageable with dose reductions.
Estonian: Ohutuse aspektist on kõrvaltoimetega üldiselt võimalik toime tulla annuse vähendamise abil.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Zejula can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Zejula kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.